(583) Sotrovimab in Heart Transplant Recipients with Covid-19 in the Omicron Era: A National Transplant Center Experience

PURPOSE: Early use of anti-SARS-CoV-2 monoclonal antibodies has shown to be a safe option to reduce hospitalization and death in solid organ transplant recipients with COVID-19. Real world data regarding sotrovimab in heart transplant (HT) recipients is scarce. We aim to describe our experience in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia, C.N. Perez, Hewitt, K., Aslam, S., Parlon, B., Baby, T., Lynch, B., Hannan, M., Ging, P., Giblin, G., Murphy, K., Joyce, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068102/
http://dx.doi.org/10.1016/j.healun.2023.02.598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068102/
http://dx.doi.org/10.1016/j.healun.2023.02.598

Ejemplares similares